Hollis-Eden: Preclinical data promising for compounds targeting prostate cancer

By E. Janene Geiss

Philadelphia, Sept. 13 - Hollis-Eden Pharmaceuticals, Inc. said Wednesday that data detailing activity of steroid compounds in preclinical models of hormone refractory prostate cancer show that these compounds can inhibit adrenal steroid-induced generation and proliferation of prostate cancer tumors common in late-stage disease.

In commonly used mouse models for hormone refractory prostate cancer in humans, treatment with one of Hollis-Eden's compounds, HE3235, reduced tumor incidence in a dose-dependent fashion and, in the high-dose group, completely prevented tumor growth compared to 92% tumor incidence in mice, according to a news release from the San Diego pharmaceutical company.

In its research, Hollis-Eden said it screened compounds from its library that inhibited adrenal androgen stimulated proliferation of human LnCaP prostate cancer cells in vitro. This system, designed to mimic hormone refractory prostate cancer in humans, was used to identify lead compounds that would then be tested in the mice model for hormone refractory prostate cancer.

The company presented these findings at the 12th International Congress on Hormonal Steroids, Hormones & Cancer held this week in Athens.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.